Join Paid Research Studies for Chronic Illness in Australia

Effect of an Eccentric Exercise Program on Quality of Life and Function in People With Chronic Heart Failure.

Condition: Chronic Heart Failure
Interventions: Other: walking and light weights; Other: eccentric aerobic exercise; Other: concentric aerobic exercise
Sponsors: La Trobe University; Northern Hospital, Australia
Recruiting
Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents

Conditions: Rheumatoid Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis
Interventions: Biological: Originator; Biological: Biosimilar
Sponsors: Opal Rheumatology Ltd.; Merck Sharp & Dohme Corp.
Recruiting
A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

Condition: Giant Cell Arteritis (GCA)
Interventions: Drug: Upadacitinib; Drug: Corticosteroid (CS); Other: Placebo
Sponsor: AbbVie
Recruiting
Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma

Conditions: Recurrent Neuroblastoma; Stage 2A Neuroblastoma; Stage 2B Neuroblastoma; Stage 3 Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma
Interventions: Other: Cytology Specimen Collection Procedure; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

Condition: Crohn's Disease
Interventions: Other: Matching placebo for upadacitinib; Drug: upadacitinib
Sponsor: AbbVie
Recruiting
Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)

Condition: Ankylosing Spondylitis
Intervention: Drug: Tofacitinib
Sponsor: Pfizer
Recruiting
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Abemaciclib; Drug: Standard Adjuvant Endocrine Therapy
Sponsors: Eli Lilly and Company; NSABP Foundation Inc
Recruiting
A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion (Cadenza Study)

Condition: Agglutinin Disease, Cold
Interventions: Drug: Sutimlimab; Drug: Placebo
Sponsor: Bioverativ Therapeutics Inc.
Recruiting
A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy

Condition: Crohn's Disease
Interventions: Drug: Upadacitinib; Drug: Placebo for Upadacitinib
Sponsor: AbbVie
Recruiting
A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

Condition: Psoriatic Arthritis
Interventions: Biological: placebo for rizankizumab; Biological: risankizumab
Sponsor: AbbVie
Not yet recruiting
A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

Condition: Psoriatic Arthritis
Interventions: Biological: placebo for rizankizumab; Biological: risankizumab
Sponsor: AbbVie
Not yet recruiting
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus
Interventions: Drug: Baricitinib; Drug: Placebo
Sponsors: Eli Lilly and Company; Incyte Corporation
Recruiting
A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Condition: Crohn's Disease
Interventions: Drug: placebo for risankizumab IV; Drug: risankizumab SC; Drug: risankizumab IV
Sponsor: AbbVie
Recruiting
A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989

Condition: Crohn's Disease
Interventions: Drug: placebo for risankizumab SC; Drug: risankizumab IV; Drug: placebo for risankizumab IV; Drug: risankizumab SC
Sponsor: AbbVie
Recruiting
A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: placebo for risankizumab; Drug: risankizumab IV; Drug: risankizumab SC
Sponsor: AbbVie
Recruiting
Observational Study of Obstructive Lung Disease (NOVELTY)

Conditions: Asthma; COPD; Chronic Obstructive Pulmonary Disease
Interventions: Procedure: Blood draw; Procedure: Urine; Procedure: Lung function measurements; Procedure: Fractional Exhaled Nitric Oxide (FENO)
Sponsors: AstraZeneca; Parexel
Recruiting

Join Paid Research Studies for Chronic Illness in Australia

Welcome to Paid Research Studies